Lenalidomid Devatis

Lenalidomide, the active ingredient in Lenalidomid Devatis, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of multiple myeloma and myelodysplastic syndromes, targeting malignant plasma cells and abnormal bone marrow clones in adult patients. It is indicated for adult patients with relapsed or refractory disease and is administered under specialist supervision.

GNH USA supplies Lenalidomid Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company ensures consistent quality and regulatory compliance for oncology therapeutics.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and bone marrow disorders. - Multiple myeloma: improves progression‑free survival and reduces disease burden. - Relapsed/refractory multiple myeloma: provides a therapeutic option after prior therapies. - Myelodysplastic syndromes: reduces transfusion dependence and may improve blood counts.

Adverse reactions may occur with lenalidomide therapy.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations indicating liver stress. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thrombotic risk: evaluate history of clotting disorders and consider prophylaxis. - Avoid pregnancy: contraindicated; enforce effective contraception. - Adjust for renal impairment: dose may need modification in reduced kidney function. - Store at ambient temperature: keep in the original pack, protect from moisture and light. - Keep out of reach of children: ensure secure storage to prevent accidental ingestion.

Lenalidomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Thalidomide: combined use heightens teratogenic risk. - Live vaccines: immunosuppression can reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to thrombosis risk. - NSAIDs: may increase risk of renal impairment when combined.